肺癌患者化疗前后血清IGF-Ⅱ、EGF和CYFRA21-1检测的临床意义

Clinical Significance of Measurement of Changes of Serum IGF-Ⅱ,EGF and CYFRA21-1 Levels After Chemotherapy in Patients with Lung Cancer

目的:探讨了肺癌患者化疗前后血清IGF-Ⅱ、EGF和CYFRA21-1水平的变化及意义。方法:应用放射免疫分析和化学发光法对39例肺癌患者进行了化疗前后血清IGF-Ⅱ、EGF和CYFRA21-1检测,并与35名正常健康人作比较。结果:肺癌患者在化疗前血清IGF-Ⅱ、EGF和CYFRA21-1水平均非常显著地高于正常人组(P<0.01)。经化疗6个月后与正常人组作比较仍有差异(P<0.05)。结论:肺癌的发生、发展与血清IGF-Ⅱ、EGF和CYFRA21-1水平的变化密切相关。

Objective To study the clinical significance of changes of serum IGF-Ⅱ,EGF and CYFRA21-1 levels after chemotherapy in patients with lung cancer.Methods Serum IGF-Ⅱ,EGF（with RIA）,and CYFRA21-1（with ECLIA）levels were determined both before and after chemotherapy in 39 patients with lung cancer as well as once in 35 controls.Results Before chemotherapy,serum IGF-Ⅱ,EGF and CYFRA21-1 levels were significantly higher in the patients than those in controls（P〈0.01）.Six months after chemotherapy,serum IGF-Ⅱ,EGF and CYFRA21-1 levels dropped markedly,but remained significantly higher than those in controls（P〈0.05）.Conclusion The development of lung cancer in patients was closely related to the serum IGF-Ⅱ,EGF and CYFRA21-1 levels.